Cotherapy with recombinant human insulin-like growth factor I and insulin improves glycemic control in type I diabetes

Diabetes Care

Volumn 22, Issue 4, 1999, Pages 585-592

  Thrailkill, Kathryn M ^a   Quattrin, Teresa ^b   Baker, Lester ^b   Kuntze, Joyce E ^b   Compton, Peter G ^b   Martha Jr , Paul M ^b  

^a UNIVERSITY OF KENTUCKY   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; ISOPHANE INSULIN; NEUTRAL INSULIN; RECOMBINANT SOMATOMEDIN C; SOMATOMEDIN BINDING PROTEIN; SOMATOMEDIN C;

ADOLESCENT; ADULT; AGED; ARTICLE; BLOOD GLUCOSE MONITORING; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES CONTROL; DIABETIC RETINOPATHY; DOSE CALCULATION; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EDEMA; FEMALE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN HYPOGLYCEMIA; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PAIN; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME;

EID: 0033035850     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.22.4.585     Document Type: Article

References (31)

1. Cusi K, DeFronzo RA: Treatment of NIDDM, IDDM, and other insulin-resistant states with IGF-I: physiological and clinical considerations. Diabetes Reviews 3:206-236, 1995
2. Shishko PI, Dreval AV, Abugova IA, Zarjarny IU, Goncharov VC: Insulin-like growth factors and binding proteins in patients with recent-onset type 1 (insulin-dependent) diabetes mellitus: influence of diabetes control and intraportal insulin infusion. Diabetes Res Clin Pract 25:1-12, 1994
3. Taylor AM, Dunger DB, Grant DB, Preece MA: Somatomedin-C/IGF-I measured by radioimmunoassay and somatomedin bioactivity in adolescents with insulin dependent diabetes compared with puberty matched controls. Diabetes Res 9:177-181, 1988
4. Edge JA, Dunger DB, Mathews DR, Gilbert JP, Smith CP: Increased overnight growth hormone concentrations in diabetics compared with normal adolescents. J Clin Endocrinol Metab 71:1356-1362, 1990
5. Batch JA, Baxter RC, Werther G: Abnormal regulation of insulin-like growth factor binding proteins in adolescents with insulin-dependent diabetes. J Clin Endocrinol Metab 73:964-968, 1991
6. Strasser-Vogel B, Blum WF, Past R, Kessler U, Hoeflich A, Meiler B, Keiss W: Insulin-like growth factor (IGF)-I and -II and IGF-binding proteins-1, -2, and -3 in children and adolescents with diabetes mellitus: correlation with metabolic control and height attainment. J Clin Endocrinol Metab 80:1207-1213, 1995
7. Radetti G, Paganini C, Antoniazzi F, Pasquino B, Valentini R, Gentili L, Tato I.: Growth hormone-binding proteins, IGF-I and IGF-binding proteins in children and adolescents with type 1 diabetes mellitus. Horm Res 47:110-115, 1997
8. Rajkumar K, Barron D, Lewitt MS, Murphy LJ: Growth retardation and hyperglycemia in insulin-like growth factor binding protein-1 transgenic mice. Endocrinology 136:4029-4034, 1995
9. Lewitt MS, Denyer GS, Cooney GJ, Baxter RC: Insulin-like growth factor-binding protein-1 modulates blood glucose levels. Endocrinology 129:2254-2264, 1991
10. Jacob RJ, Sherwin RS, Bowen L, Fryburg D, Fagin KD, Tamborlane WV, Shulman GI: Metabolic effects of IGF-I and insulin in spontaneously diabetic BB/w rats. Am J Physiol 260:E262-E268, 1991
11. Levin N, Brunet C, Won WB, Oster MH, Mortensen D, Ma Y-H, Clark R: Serum glucose lowering effects of insulin-like growth factor-I (IGF-I) in a rodent model of NIDDM (Abstract). 77th Annual Meeting of the Endocrine Society P1-P272, 1995
12. Giacca A, Gupta R, Efendic S, Hall K, Skottner A, Lickley L, Vranic M: Differential effects of IGF-I and insulin on glucoregulation and fat metabolism in depancreatized dogs. Diabetes 39:340-347, 1990
13. The Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977-986, 1993
14. The Diabetes Control and Complications Trial Research Group: Adverse events and their association with treatment regimens in the diabetes control and complications trial. Diabetes Care 18:1415-1427, 1995
15. Quattrin T, Thrailkill K, Baker L, Litton J, Dwigun K, Rearson M, Poppenheimer M, Giltinan D, Gesundheit N, Martha P Jr.: Dual hormonal replacement with insulin and recombinant human insulin-like growth factor I in IDDM: effects on glycemic control, IGF-I levels and safety profile. Diabetes Care 20:374-380, 1997
16. Thrailkill K, Quattrin T, Baker L, Litton J, Dwigun K, Rearson M, Poppenheimer M, Kotlovker D, Giltinan D, Gesundheit N, Martha Jr P: Dual hormonal replacement therapy with insulin and recombinant human insulin-like growth factor (IGF)-I in insulin-dependent diabetes mellitus: effects on the growth hormone/IGF/IGF-binding protein system. J Clin Endocrinol Metab 82:1181-1187, 1997
17. Feman SS, Leonard-Martin TC, Andrews JS, Armbruster CC, Burge TL, Debelak JD, Lanier A, Fischer AG: A quantitative system to evaluate diabetic retinopathy from fundus photographs. Invest Ophthalmol Vis Sci 36:174-181, 1995
18. Quarmby V, Quan C, Ling V, Compton P, Canova-Davis E: How much insulin-like growth factor I (IGF-I) circulates? Impact of standardization on IGF-I assay accuracy. J Clin Endocrinol Metab 83:1211-1216, 1998
19. Appen RE, Chandra SR, Klein R, Myers FL: Diabetic papillopathy. Am J Ophthalmol 90:203-209, 1980
20. Cheetham TD, Jones J, Taylor AM, Holly J, Mathews DR, Dunger DB: The effects of recombinant insulin-like growth factor I administration on growth hormone levels and insulin requirements in adolescents with type I (insulin-dependent) diabetes mellitus. Diabetologia 36:676-681, 1993
21. Bach MA, Chin E, Bondy CA: The effects of subcutaneous insulin-like growth factor-I infusion in insulin-dependent diabetes mellitus. J Clin Endocrinol Metab 79:1040-1045, 1994
22. Bloedow D, Reimann J, Kuntze J, Giltinan D, Blevins T, Schwartz S, Martha P: IGF-I, IGFBPs, IGI-II, and GH profiles in IDDM subjects treated with rhIGF-I for 14 days (Abstract). 79th Annual Meeting of the Endocrine Society P3-131, 1997
23. Acerini CL, Patton CM, Savage MO, Kernell A, Westphal O, Dunger DB: Randomised placebo-controlled trial of human recombinant insulin-like growth factor I plus intensive insulin therapy in adolescents with insulin-dependent diabetes mellitus. Lancet 350:1199-1204, 1997
24. Asada T, Ogawa T, Iwai M, Shimomura K, Kobayashi M: Recombinant insulin-like growth factor I normalizes expression of renal glucose transporters in diabetic rats. Am J Physiol 273:F27-F37, 1997
25. Hussain MA, Schmitz O, Mengel A, Keller A, Christiansen JS, Zapf J, Froesch ER: Insulin-like growth factor I stimulates lipid oxidation, reduces protein oxidation, and enhances insulin sensitivity in humans. J Clin Invest 92:2249-2256, 1993
26. Bach MA, Chin E, Bondy CA: The effects of subcutaneous insulin-like growth factor-I infusion in insulin-dependent diabetes mellitus. J Clin Endocrinol Metab 79:1040-1045, 1994
27. Zenobi PD, Jaeggi-Groisman SE, Riesen WF, Roder ME, Froesch ER: Insulin-like growth factor-I improves glucose and lipid metabolism in type 2 diabetes. J Clin Invest 90:2234-2241, 1992
28. Schoenle EJ, Zenobi PD, Toresarie T, Wender EA, Zachman M, Froesch ER: Recombinant insulin like growth factor I (rhIGF-I) reduces hyperglycemia in patients with insulin resistance. Diabetologia 34:675-679, 1990
29. Morrow LA, O'Brien MB, Moller DE, Flier JS, Moses AC: Recombinant human insulin-like growth factor-I therapy improves glycemic control and insulin action in the type A syndrome of severe insulin resistance. J Clin Endocrinol Metab 79:205-210, 1994.
30. Moses AC, Young SCJ, Morrow LA, O'Brien M, Clemmons DR: Recombinant human insulin-like growth factor I increases insulin sensitivity and improves glycemic control in type II diabetes. Diabetes 45:91-100, 1996
31. Smith LEH, Kopchick JJ, Chen W, Knapp J, Kinose F, Daley D, Foley E, Smith RG, Schaeffer JM: Essential role of growth hormone in ischemia-induced retinal neovascularization. Science 276:1706-1708, 1997